Different brain atrophy patterns may explain variability in Alzheimers disease symptoms

October 7, 2016
Mathematical modeling of brain scans of patients with Alzheimer's disease and others at risk for the disorder has allowed the identification of three atrophy factor patterns, based on the loss of gray matter throughout major areas of the brain, which may help explain the variations in symptoms occurring in individual patients. Credit: Xiuming Zhang, National University of Singapore

Mathematical modeling of the brain scans of patients with Alzheimer's disease and others at risk for the devastating neurodegenerative disorder has identified specific patterns of brain atrophy that appear to be related to the loss of particular cognitive abilities. In their report that has been published online in the Proceedings of the National Academy of Sciences, a team of researchers at Massachusetts General Hospital (MGH) and the National University of Singapore describe how different atrophy patterns may explain the different ways that Alzheimer's disease can be manifested in individual patients.

"The symptom severity and neurodegeneration can vary widely across patients in Alzheimer's disease," says Thomas Yeo, PhD, of the Martinos Center for Biomedical Imaging at MGH. "Our work shows that participants in this study exhibit at least three atrophy patterns - cortical, temporal or subcortical - that are associated with variability in cognitive decline not only in patients diagnosed with Alzheimer's but also in individuals with mild cognitive impairment or those who are cognitively normal but are at risk for Alzheimer's." In addition to his affiliation with the Martinos Center, Yeo is an assistant professor in the Department of Electrical and Computer Engineering, Clinical Imaging Research Centre and Singapore Institute for Neurotechnology at the National University of Singapore.

The study analyzed data collected as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI), a multi-institutional project to develop biomarkers - including blood tests, cerebrospinal fluid tests, and imaging studies - that can be used for diagnosis or in clinical trials. Yeo and his team - including investigators at the MGH and in Singapore - analyzed MR images taken of the brains of 378 ADNI participants when they enrolled in the study. Of these participants, 188 had been diagnosed with Alzheimer's disease; the others - 147 with mild cognitive impairment and 43 who were cognitively normal - were at increased risk based on levels in their brains of the beta-amyloid plaques that are characteristic of the disease.

As a first step, the research team analyzed data from the baseline structural MRIs using a mathematical model that estimated the probability that particular details of each image were associated with atrophy of a specific location within the brain. Based on the location of atrophy factors, they determined three atrophy factor patterns: cortical - representing atrophy in most of the cerebral cortex; temporal - indicating atrophy in the temporal cortex (the cortical lobe behind the ears), hippocampus and amygdala; and subcortical, indicating atrophy in the cerebellum, striatum and thalamus, structures at the base of the brain.

Analysis of study participant scans taken two years later indicated that atrophy factor patterns were persistent in individuals and did not reflect different stages of disease. Most participants - including those in the and cognitively normal groups - showed levels of more than one atrophy factor.

Behavioral and cognitive tests of study participants taken at six-month intervals indicated associations between particular atrophy factor patterns and specific cognitive deficits. Individuals in whom temporal atrophy predominated had greater problems with memory, while cortical atrophy was associated with difficulties with executive function - the ability to plan and to accomplish goals. Individual differences in how atrophy factors are distributed within the brain may allow prediction of the rate at which cognitive abilities would be expected to decline.

"Most previous studies focused on patients already diagnosed, but we were able to establish distinct atrophy patterns not only in diagnosed patients but also in at-risk participants who had mild impairment or were cognitively normal at the outset of the study," Yeo says. "That is important because the neurodegenerative cascade that leads to Alzheimer's starts years, possibly decades, before diagnosis. So understanding different atrophy patterns among at-risk individuals is quite valuable.

He adds, "Previous studies assumed that an individual can only express a single neurodegenerative pattern, which is highly restrictive since in any aged person there could be multiple pathological factors going on at the same time - such as vascular impairment along with the amyloid plaques and tau tangles that are directly associated with Alzheimer's. So individuals who are affected by multiple, co-existing pathologies might be expected to exhibit multiple atrophy patterns."

Future research could further determine whether and how these atrophy patterns relate to the distribution of amyloid and tau and the mechanisms by which they affect specific , Yeo explains. The same analytic approach also could be applied to other types of patient data and extended to other neurodegenerative disorder that produce varying symptom patterns, such as Parkinson's disease and autism.

Explore further: Two Alzheimer's risk genes linked to brain atrophy, promise future blood markers

More information: Xiuming Zhang et al, Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease, Proceedings of the National Academy of Sciences (2016). DOI: 10.1073/pnas.1611073113

Related Stories

Two Alzheimer's risk genes linked to brain atrophy, promise future blood markers

December 23, 2015
Two genetic variants previously linked to Alzheimer's disease have been more specifically tied to brain atrophy that is characteristic of the disease.

Memory loss not enough to diagnose Alzheimer's

September 13, 2016
Relying on clinical symptoms of memory loss to diagnose Alzheimer's disease may miss other forms of dementia caused by Alzheimer's that don't initially affect memory, reports a new Northwestern Medicine study.

Widespread brain atrophy detected in Parkinson's disease with newly developed structural pattern

December 12, 2011
Atrophy in the hippocampus, the region of the brain known for memory formation and storage, is evident in Parkinson's disease (PD) patients with cognitive impairment, including early decline known as mild cognitive impairment ...

Researchers discover gender-based differences in Alzheimer's disease

November 26, 2012
All patients with Alzheimer's disease (AD) lose brain cells, which leads to a shrinking, or atrophy, of the brain. But the pattern of gray matter loss is significantly different in men and women, according to a study presented ...

Test for Alzheimer's disease predicts cognitive decline in Parkinson's disease

December 12, 2011
A method of classifying brain atrophy patterns in Alzheimer's disease patients using MRIs can also detect cognitive decline in Parkinson's disease, according to a new study by researchers from the Perelman School of Medicine ...

Recommended for you

Thinking 'out-of-the-box' may build a better brain and prevent dementia

September 25, 2017
More than 5 million Americans today are affected by Alzheimer's disease (AD). If nothing is done to stop this upward trajectory, there will be more than 16 million people with AD in the United States and more than 60 million ...

Multi-gene test predicts Alzheimer's better than APOE E4 alone

September 22, 2017
A new test that combines the effects of more than two dozen genetic variants, most associated by themselves with only a small risk of Alzheimer's disease, does a better job of predicting which cognitively normal older adults ...

Personality changes don't precede clinical onset of Alzheimer's, study shows

September 21, 2017
For years, scientists and physicians have been debating whether personality and behavior changes might appear prior to the onset of Alzheimer's disease and related dementias.

Newly ID'd role of major Alzheimer's gene suggests possible therapeutic target

September 20, 2017
Nearly a quarter century ago, a genetic variant known as ApoE4 was identified as a major risk factor for Alzheimer's disease—one that increases a person's chances of developing the neurodegenerative disease by up to 12 ...

Is the Alzheimer's gene the ring leader or the sidekick?

September 15, 2017
The notorious genetic marker of Alzheimer's disease and other forms of dementia, ApoE4, may not be a lone wolf.

Potential noninvasive test for Alzheimer's disease

September 6, 2017
In the largest and most conclusive study of its kind, researchers have analysed blood samples to create a novel and non-invasive way of helping to diagnose Alzheimer's disease and distinguishing between different types of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.